Andrew Cheng - 16 Dec 2024 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role: President and CEO, Director
Signature: /s/ Jonathan Young, Attorney-in-Fact
Issuer symbol: AKRO
Transactions as of: 16 Dec 2024
Net transactions value: $0
Form type: 4
Filing time: 18 Dec 2024, 20:50:13 UTC
Previous filing: 12 Dec 2024
Next filing: 27 Jan 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKRO	Common Stock	Award	$0	+98,500	+16%	$0.000000	696,062	16 Dec 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKRO	Stock Option (Right to Buy)	Award	$0	+295,600		$0.000000	295,600	16 Dec 2024	Common Stock	295,600	$29.23	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in eight (8) equal semi-annual installments, commencing from December 16, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F2	This option shall vest and become exercisable in forty-eight (48) equal monthly installments, commencing from December 16, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.